Thoughts about the classification of small vessel vasculitis

Journal of Nephrology

Volumn 17, Issue SUPPL. 8, 2004, Pages

  Falk, Ronald J ^a   Jennette, J Charles ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Arterials; Arteries; Arteritis; Classification; Diagnosis; Glomerulonephritis; Pathology

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ANCA ASSOCIATED VASCULITIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE CLASSIFICATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MICROSCOPIC POLYANGIITIS; NECROTIZING ARTERITIS; PLASMAPHERESIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REMISSION; REVIEW; WEGENER GRANULOMATOSIS; CLASSIFICATION; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; VASCULITIS;

EID: 16644397007     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Rokitansky K. Ueber einige der wichtigsten Krankheiten der Arterian. Denkschriften der Kais Akad der Wissensch besonders abgedruckt 1852; 4: 49.
2. Eppinger H. Pathogenesis (histogenesis und aetiologie) der aneurysmen einschliesslich des aneurysma equi verminosum. Patholog.-anatom. Stidien. Arch Klin Chir 1887; 35 (suppl): S1-553.
3. Kussmaul A, Maier R. Uber eine bisher nicht beschreibene eigenthumliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellahmung einhergeht. Dtsch Arch Klin Med 1866; 1: 484-518.
4. Zeek PM, Smith CC, Weeter JC. Studies on periarteritis nodosa. III. The differentiation between the vascular lesions of periarteritis nodosa and of hypersensitivity. Am Pathol 1948; 24: 889-917.
5. Zeek PM. Periarteritis nodosa: a critical review. Am J Clin Pathol 1952; 22: 777-90.
6. Godman GC, Churg J. Wegener's granulomatosis. Pathology and review of the literature. Arch Pathol Lab Med 1954; 58: 533-53.
7. Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
8. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. Q J Med 1948; 17: 175-202.
9. Heptinstall RH. Polyarteritis (periarteritis) nodosa, Wegener's syndrome, and other forms of vasculitis. Pathology of the kidney. Boston: Little Brown and Company 1992; 1097-162.
10. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285: 606.
11. Hall JB, Wadham BM, Wood CJ, Ashton V, Adam WR. Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust NZJ Med 1984; 14: 277-8.
12. Van Der Woude FJ, Rasmussen N, Lobatto S. Auto-antibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
13. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-7.
14. Tervaert JW, Limburg PC, Elema JD. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med 1991; 91: 59-66.
15. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degra-nulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-9.
16. Day CJ, Hewins P, Savage CO. New developments in the pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol 2003; 21 (suppl): S35-48.
17. Kallenberg CG, Rarok A, Stegeman CA, Limburg PC. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. Autoimmun Rev 2002; 1: 61-6.
18. Xiao H, Heeringa P, Hu P. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-63.
19. Yang JJ, Preston GA, Alcorta DA. Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). Kidney Int 2002; 62: 1638-49.
20. Pendergraft WF, Preston GA, Shah RR. Autoimmunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10: 72-9.
21. Falk RJ, Hogan SL, Muller KE, Jennette JC. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network (see comments). Ann Intern Med 1992; 116: 438-45.
22. Jayne D, Gaskin G. Randomised trial of cyclophosphamide versus azathioprine during remission in ANCA associated systemic vasculitis (CYCAZAREM). Clin Exp Immunol 2000; 120 (suppl 1): S74.
23. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001; 13: 48-55.
24. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737-47.
25. Jayne D, Rasmussen N, Andrassy K. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
26. Hogan SL, Nachman PH, Jennette JC, Falk RJ. Predictors of relapse in ANCA small vessel vasculitis. Clin Exp Immunol 1998; 112: 23.